Gene editing can repair mutations that prematurely halt protein synthesis, resulting in incomplete peptides that cause ...

Sanofi SA reported more hitches in the development of Bruton’s tyrosine kinase inhibitor tolebrutinib, saying the phase III Perseus study failed to meet its primary endpoint in primary progressive ...

Nephrodite Inc.'s Holly, an implantable, continuous renal replacement system, received U.S. FDA breakthrough device designation as a novel and potentially life-changing treatment for end-stage kidney ...

If at first you don’t succeed, try, try again” seems to be the motto of U.S. lawmakers – at least when it comes to the ...

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Bioretec, Heartsciences, Helio Genomics, Lunit, Natera, Neogenomics, Neurosigma, Philips, ...

The U.S. FDA recently cleared two new medical devices to treat benign prostatic hyperplasia, offering men with enlarged prostates additional treatment options which are minimally invasive. The ...

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder marked by progressive degeneration of upper and lower motor neurons, resulting in paralysis and death typically within 3-5 ...

Through the first 11 months of 2025, biopharma dealmaking remained robust with collective value reaching $261.14 billion, the highest January through November total of the past seven years and well ...

China’s clinical trial volume has surged to nearly U.S. scale and now tops Europe, sitting at about 80% of U.S. levels and roughly 10% above the EU in 2024.

Positive top-line phase III data for Immunome Inc.’s oral, once daily treatment for progressing desmoid tumors have prompted the company to say it plans to submit an NDA to the U.S. FDA in the second ...

The EU finally reached agreement on an update of the 20-year-old pharmaceutical legislation, more than five years after the EU Commission first put forward the case for reform and following two and a ...

A group of eight Democratic senators is asking biopharma companies to spill the beans about their private most-favored-nation pricing deals with U.S. President Donald Trump. Led by Sen. Ron Wyden, ...